AstraZeneca’s stock tumbled as much as 9% after a Phase III trial of Wainua failed to meet its primary endpoint in ATTR-CM, a setback for the company’s cardiovascular program and its Ionis collaboration.

The trial showed no statistically significant benefit when Wainua was added to stabiliser-based standard care versus placebo, signaling a meaningful disappointment for the drug’s development trajectory.

This coverage note indicates the story comes from a subscription-based STAT+ offering, signaling that full details are behind a paywall.

The report highlights AI-assisted generation and editorial review, with market reaction and implications for the company’s pipeline discussed.

The broader market context was weak: STOXX 600 edged up, but AstraZeneca’s drop pulled the FTSE 100 into negative territory, underscoring the stock’s influence on the index.

The article includes related content and recruitment/promo elements, but the central focus remains the trial miss and the market response.

Despite the setback, Citi maintained an overweight stance with a price target of 16,500 pence, shifting investor attention to other late-stage catalysts for 2026, such as Dato-DXd, tozorakimab, and camizestrant.

As a late-stage trial, the study’s scale underscored potential impact, though detailed results are not fully disclosed in the excerpt.

Analyst commentary described the result as a meaningful downside surprise with anticipated revisions to peak sales and long-term earnings.

AstraZeneca released a statement confirming the Missed target and said it would monitor and provide updates as more data are analyzed.

The excerpt notes no additional actionable data beyond the headline and immediate market reaction.

The piece emphasizes the share impact and frames the trial setback as the central news, with financial and developmental implications.